Adlane Soudani | Global Asset Lead Rare Disease
Ipsen

Adlane Soudani, Global Asset Lead Rare Disease, Ipsen


Adlane Soudani is Global Asset Lead at IPSEN. Adlane has 20+ years of international leadership in the pharmaceutical industry with extensive experience in the rare disease space. Over the years, Adlane has led strategic initiatives across multiple therapeutic areas, global launches, asset development and general management across multiple geographies.

Appearances:



Day 1 - Tuesday 28 October @ 11:30

Working Group 1: From Insight to Action: Leveraging Patient Experience Data Across the Rare Disease Lifecycle

Understanding patient experiences, preferences, and behaviours is critical to developing treatments that truly meet patient needs. Yet in rare diseases, capturing and applying these insights remains difficult due to small, diverse populations, delayed diagnoses, a lack of standardized methods, and limited regulatory guidance. 

This panel will explore how both qualitative, and semi-quantitative patient data can inform more effective, patient-centred decisions across the product lifecycle in the rare disease space. Experts will address key barriers, such as data integration, resource constraints, and methodological gaps, and share practical strategies and real-world examples to overcome them. 

Join the panel and gain a clear view of what meaningful patient experience data look like and how they can drive clinical development strategies, as well as pre-launch and market success

Session led by: Alira Health
last published: 06/Oct/25 16:25 GMT

back to speakers

Get involved at World Orphan Drug Congress Europe 2025

 

 

TO SPONSOR


Steph Scanlon

Steph.Scanlon@terrapinn.com

 

TO SPEAK


Abdu Kauroo
Abdu.Kauroo@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.